Press releases

The press releases are available in Swedish when no translation exists.

BioStock: Italian distributor expresses confidence in Chordate Medical's migraine treatment

Italy is Chordate Medical's most active market to date, in large part due to the distributor Vedise Hospital that has performed solid work regarding sales of K.O.S for the treatment of rhinitis. Now that Chordate has received CE marking in chronic migraine, K.O.S. will be launched as a migraine treatment in Italy. In an interview with BioStock, Vedise Hospital expresses high hopes for this launch and talks about its plans in connection with the launch.

We are a Swedish medical technology company listed on NGM Nordic SME.

Chordate has spent more than 10 years developing the Kinetic Oscillation Stimulation, K.O.S, a technique for treating rhinitis and migraine. We have a patent on K.O.S in the EU and the United States, as well as many other countries.

We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company's share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

IR contact